Enalaprilat Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 1.25 mg/m
Reference Brands: Generic formulations marketed under different names
Category:
Heart Disorder
Enalaprilat is available in Injection
and strengths such as 1.25 mg/m.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Enalaprilat is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Enalaprilat can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Enalaprilat injection is an intravenous angiotensin-converting enzyme (ACE) inhibitor used primarily in the management of hypertension when oral therapy is not feasible, such as in hospitalized or critically ill patients. It is the active metabolite of enalapril maleate, an oral prodrug, and is poorly absorbed through the gastrointestinal tract, which necessitates intravenous administration for effective therapeutic action.
Pharmacologically, enalaprilat works by competitively inhibiting the angiotensin-converting enzyme, thereby blocking the conversion of angiotensin I to angiotensin II. Angiotensin II is a potent vasoconstrictor; its inhibition results in vasodilation, leading to a reduction in systemic vascular resistance and blood pressure. Additionally, enalaprilat decreases angiotensin II-mediated aldosterone secretion from the adrenal cortex. This reduction in aldosterone promotes sodium excretion and increases water outflow, further contributing to blood pressure control.
Enalaprilat is indicated for patients who require rapid blood pressure management and cannot tolerate oral medications. Its clinical use requires careful dosing, monitoring of renal function, electrolytes, and blood pressure, as well as attention to contraindications, warnings, and potential drug interactions. Enalaprilat plays a significant role in acute care settings where controlled and effective antihypertensive therapy is essential.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing